Wired for What’s Next.
Reach your press release and disclosure targets.
Get more views with multimedia.
Track your results and refine your message.
Be the news everyone talks about.
Latest News
Today is December 06, 2020.
All times in Eastern Time.
-
CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma
(WILMINGTON, Del.--(BUSINESS WIRE)--Long-term follow-up results from the positive ACE-LY-004 Phase II trial showed patients with relapsed or refractory mantle cell lymphoma (MCL) treated with CALQU... more » -
Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual MeetingNEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood ... more »
-
Expanse Introduces Attack Surface Management for Amazon Web Services
SAN FRANCISCO--(BUSINESS WIRE)--Expanse has officially made its Expander solution available in the AWS Marketplace. more » -
Durable Clinical Benefits Induced by IMV’s T Cell Therapy in Combination With Merck’s Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual MeetingDARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq:IMV; TSX:IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and v... more »
-
Datos del estudio APOLLO muestran una respuesta clínicamente significativa del régimen de tratamiento con formulación subcutánea de DARZALEX®▼ (daratumumab) después de la primera recidiva o de las subsiguientes en mieloma múltiple
BEERSE, Bélgica--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies de Johnson & Johnson anunció los resultados del estudio APOLLO de fase III, que demuestran que el agregado de la formulaci... more » -
Daten aus der Studie APOLLO zeigen klinisch signifikantes Ansprechen auf subkutan verabreichte Formulierung DARZALEX®▼ (Daratumumab) nach erstem oder späterem Rezidiv des multiplen Myeloms
BEERSE, Belgien--(BUSINESS WIRE)--Die Janssen Pharmaceutical Companies von Johnson & Johnson legten Ergebnisse aus der Phase-3-Studie APOLLO vor, die zeigen, dass die Zugabe der subkutanen (SC)... more »
-
The 3rd Hainan Island International Film Festival opened in Sanya, Hainan, China
SANYA, Hainan, China--(BUSINESS WIRE)--On December 5th, the 3rd Hainan Island International Film Festival opened in Sanya, Hainan, China. Shen Xiaoming, secretary of Hainan Provincial Party Committ... more » -
Un dialogo che unisce scultura di radici e poesia a Kaihua, in Cina
CONTEA KAIHUA, Cina--(BUSINESS WIRE)--Il 3 dicembre si è svolto nella città di Quzhou, contea di Kaihua, provincia dello Zhejiang, in Cina, il 9° Festival culturale cinese (di Kaihua) dell'arte di ... more » -
Potential PSPS Update: Forecasted High Winds and Dry Conditions Mean PG&E Might Proactively Turn Off Power for Safety in Targeted Portions of 16 Counties and Two Tribal Communities Beginning Early Monday MorningSAN FRANCISCO--(BUSINESS WIRE)--Potential PSPS Update: Forecasted High Winds and Dry Conditions Mean PG&E Might Proactively Turn Off Power for Safety in Portions of 16 Counties more »
-
GlycoMimetics’ Uproleselan in Combination With Venetoclax/HMA Shown to Break Chemoresistance, Reduce Tumor Burden and Increase Survival in AML Model
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics’ (Nasdaq: GLYC) product candidate uproleselan — when added to a combination therapy of venetoclax and a hypomethylating agent (HMA) — was shown today ... more » -
Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from an ongoing Phase 1 first-in-human dose escalation study (NCT0314... more » -
Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma
BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the combined Phase 1b/2 CARTITUDE-1 study (NCT03548207) eval... more » -
ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting more » -
Long-Term Data for bluebird bio’s betibeglogene autotemcel (beti-cel) Gene Therapy Show Patients Across Ages and β-thalassemia Genotypes Achieve Transfusion Independence and Remain Free from Transfusions Up to Six Years Presented at 62nd ASH Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today presented updated long-term efficacy and safety results reflecting up to six years of data for betibeglogene autotemcel ge... more » -
Legend Biotech Announces Phase 1b/2 Study Data of Cilta-cel, an Investigational BCMA CAR-T, Showing Early, Deep, and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel ce... more »